Iannitto E, Ferrero S, Bommier C, Drandi D, et al. Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study. Haematologica 2024 Mar 14. doi: 10.3324/haematol.2023.284109.
PMID: 38497158